UK cost agency recommends new Sanofi MS pill

LONDON Fri Dec 6, 2013 6:59am EST

Related Topics

LONDON Dec 6 (Reuters) - Britain's healthcare cost watchdog NICE has recommended that the state health service use Sanofi's new multiple sclerosis pill Aubagio, which will be supplied at a discount.

The National Institute for Health and Clinical Excellence (NICE) - the body that decides if drugs should be paid for - said on Friday its final draft guidance recommended Aubagio, or teriflunomide, for adults with relapsing-remitting multiple sclerosis.

The drug's list price is 13,529 pounds ($22,100) per patient a year but the size of the discount has not been disclosed.

On Thursday, NICE said it needed more information before deciding if a separate Sanofi drug for the disease - the injectable treatment Lemtrada - was worth using.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.